论文部分内容阅读
髓源性抑制细胞(myeloid-derived suppressor cell,MDSC)是一群具有免疫抑制作用的细胞,其在外周血中的表达规律与非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的外周免疫逃逸及临床分期密切相关。本研究纳入116例NSCLC患者及30例健康者,流式细胞术检测外周血PBMC中MDSC、调节性T细胞(regulatory T cell,Treg)的比例,研究其与临床分期、病理及免疫的相关规律。结果显示:与健康组比较,粒系髓源性抑制细胞(G-MDSC)、单核系髓源性抑制细胞(M-MDSC)在NSCLC外周血中比例升高,具有统计学意义(P<0.05);G-MDSC、病理类型与临床分期具有相关性(n=116,r=0.330,P<0.001;n=116,r=0.441,P<0.001),而M-MDSC、Treg与临床分期之间未发现相关性(n=116,r=-0.053,P=0.558;n=116,r=0.173,P=0.052);G-MDSC与Treg具有相关性(n=116,r=0.343,P<0.001)且与病理类型也呈现正相关(r=0.333,P<0.001);而M-MDSC与Treg未发现相关性(r=0.122,P=0.174),与病理类型不具有相关性(r=-0.143,P=0.109)。研究表明NSCLC患者外周血PBMC中MDSC比例升高,其中G-MDSC与NSCLC临床分期及Treg呈正相关,调控MDSC的表达有望成为防治肺癌发生及术后复发与转移的新策略[临床研究国际注册号NCT02603003]。
Myeloid-derived suppressor cells (MDSCs) are a group of immunosuppressive cells whose expression in peripheral blood is immunized with peripheral blood of non-small cell lung cancer (NSCLC) patients Escape and clinical stage are closely related. In this study, 116 patients with NSCLC and 30 healthy controls were enrolled in this study. Flow cytometry was used to detect the percentage of MDSCs and regulatory T cells (Tregs) in peripheral blood PBMCs and their correlations with clinical stage, pathology and immunology . The results showed that the proportion of G-MDSCs and M-MDSCs in peripheral blood of NSCLC was significantly higher than that of healthy group (P < 0.05). The correlation between M-MDSC, pathological type and clinical stage (n = 116, r = 0.330, P <0.001; n = 116, r = 0.441, P <0.001) There was no correlation between G-MDSC and Treg (n = 116, r = -0.053, P = 0.558; n = 116, r = 0.173, P = (R = 0.333, P <0.001). However, no correlation was found between M-MDSC and Treg (r = 0.122, P = 0.174), but not with pathological types r = -0.143, P = 0.109). Studies have shown that NSCLC patients with peripheral blood PBMC MDSC ratio increased, of which G-MDSC and NSCLC clinical stage and Treg was positively correlated, the regulation of MDSC expression is expected to become a new strategy for prevention and treatment of lung cancer recurrence and metastasis [Clinical Research International Registration Number NCT02603003].